Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, released its financial results for the three months and twelve months ended June 30, 2022.

Q4 2022 Financial Highlights

Fiscal Year 2022 Financial Highlights

ANEB-001 Clinical Trial

The company’s lead product candidate, ANEB-001, is being developed as a potential treatment to reverse the negative effects of acute cannabinoid intoxication (ACI). The signs and symptoms of ACI include profound sedation, anxiety, panic, hallucinations, and psychosis. More than 1.7 million …

Full story available on Benzinga.com